WuXi Biologics (WXIBF)
WuXi Biologics (Cayman) Inc. is a healthcare company listed on OTC Markets under the ticker WXIBF. Organized as an investment holding company, it provides integrated solutions for biologics discovery, development, and manufacturing across markets including mainland China, North America, Europe, Singapore, Japan, South Korea, and Australia. The company operates through two segments, Biologics and XDC, and supports programs from early discovery and concept work through IND preparation, CMC, and downstream process development. Its platform portfolio includes technologies such as WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh. WuXi Biologics also provides consulting, testing, clinical and manufacturing services, vaccine CDMO activities, and related sales and marketing functions. Headquartered in Wuxi, China, the company was incorporated in 2014.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-WXIBF
|
$6.77
|
-31.9% Downside
|
Overvalued
|
—
|
—
|
—
|
Great
|
—
|
—
|
—
|
0.0%
|
August 26, 2026
|
27.6x
|
2.9x
|
6.2x
|
20.316 B
|
17.989 B
|
2.1%
|
90.3%
|
12.5
|
—
|
54.1%
|
